Real-World Assessment of Efficacy and Safety Parameters for Dapagliflozin in Management of Type 2 Diabetes Mellitus: REWARD Study

Introduction: While ample evidence on improved glycemic control, weight reduction, and lowered blood pressure (BP) with sodium-glucose cotransporter type 2 inhibitors (SGLT2is) exists, real-world data on the potential benefit of SGLT2i on the diabetic population in the Middle East are lacking. The a...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ahmed Hassoun, Denish Kumar Dhanwal, Jalal Nafach, Yasmin Ajaz, Asif Majid Khan, Abdullah Ben Nakhi, Monira AlArouj, Khadija Hafidh, Majdi AlNajjar, Ahmed Reyas, Sana Qamar, Mohamed Alsayed, Ahmad Bdair
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Knowledge E 2022-01-01
Edice:	Dubai Diabetes and Endocrinology Journal
Témata:	dapagliflozin sodium-glucose cotransporter type 2 sodium-glucose cotransporter type 2 inhibitors diabetes mellitus type 2 diabetes mellitus type 2 diabetes
On-line přístup:	https://www.karger.com/Article/FullText/519871
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!